In California, Codexis announced that the company has signed an agreement with Shell to expand Codexis’ ability to commercialize its CodeXymeTM cellulase enzymes under a royalty-bearing, non-exclusive license to develop, manufacture, use and sell cellulase enzymes developed according to the companies’ Amended and Restated Collaborative Research Agreement. It also announced a workforce reduction as part of its effort to control expenses and conserve cash for its ongoing and future programs following the termination of the Shell Research Agreement and the corresponding loss of ongoing funding for FTEs under the Shell Research Agreement. This action will reduce Codexis’ workforce by approximately 133 employees effective October 30, 2012.

Related Articles
- Codexis pressures Shell for extension of research partnership
- Codexis, Shell redraw the advanced biofuels map with global enzyme rights deal
- EnWave Signs commercial license and equipment service agreement with an unnamed North American Enzyme Company
- Cereplast reports $30 million loss for fiscal 2012
- Codexis, Shell to part company
- Ceres announces $8.97 million lost for Q2 2013
- Global Analysts project 135 billion gallon biofuels market by 2018
- Raymond James affirms Market Perform for Codexis, citing biofuels opportunity, uncertain timelines
- Codexis commences pre-IPO road show
- Codexis, Dupont, Shell, Danisco, Novozymes, Monsanto and Syngenta added to Biofuels Digest stock index
- Shell, Cosan close $12B JV – Iogen, Codexis holdings transferred to Raizen
- Shell takes stake in Virent; re-ups with Iogen through 2012; Shell and its Biofuels Babies in review
- Shell exits algae as it commences "Year of Choices"
- Transformative Technologies: Genencor launches new enzyme as white biotechnologies surge
- Codexis handily beats Street consensus in Q3 earnings
Tags: California, Codexis, enzyme, Shell
Category: Producer News
Comments (0)
Trackback URL | Comments RSS Feed
There are no comments yet. Why not be the first to speak your mind.